Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients

BMC Clinical Pathology

George Fountzilas⁵  Elisabeta Ciuleanu⁶  Vassilios Vassiliou³  Dimitrios Andreopoulos³  Epaminontas Samantas¹  Sofia Chrysafi²  Liliana Resiga⁶  Georgia Karayannopoulou⁴  Mattheos Bobos²  Dimitrios Krikelis⁵ 

[1] Third Department of Medical Oncology, “Agii Anargiri” Cancer Hospital, Athens, Greece;Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece;Department of Radiation Oncology, Bank of Cyprus Oncology Centre, Nicosia, Cyprus;Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece;Department of Medical Oncology “Papageorgiou” Hospital, Aristotle University of Thessaloniki School of Medicine, Ring Road of Thessaloniki, Nea Efkarpia, Thessaloniki, PC, 56403, Greece;Department of Pathology, “Ion Chiricuta” Cancer Institute, Cluj, Romania

关键词: Protein-expression profiling;    Immunohistochemistry;    Caucasian patients;    Nasopharyngeal carcinoma;   

Others  :  1085148
DOI  :  10.1186/1472-6890-13-1

 received in 2012-10-06, accepted in 2013-01-24,  发布年份 2013

【 摘 要 】

Background

Since scarce data exist on the pathogenesis of nasopharyngeal carcinoma in Caucasian patients, we attempted to elucidate the responsible molecular pathways in this patient population.

Methods

Formalin-fixed paraffin-embedded tumor tissue samples from 107 patients, diagnosed with locally-advanced nasopharyngeal carcinoma and treated with chemotherapy or chemo-radiotherapy, were analyzed by immunohistochemistry for the expression of the following proteins: E-cadherin, P-cadherin, Fascin-1, Cyclin D1, COX-2, EGFR, VEGF-A, VEGF-C, VEGFR-2, VEGFR-3, ERCC1, p53, p63, Ki67, MAPT, phospho-p44/42MAPK, PTEN, phospho-AKT, phospho-mTOR, and phospho-GSK-3β. EBER status was assessed by in situ hybridization. The majority of the cases were included in tissue microarray. All stains were performed and assessed centrally by two pathologists. The median follow-up time was 76.8 (42.3 – 99.2) months.

Results

Biomolecules expressed in >90% of cases were: p53, COX-2, P-cadherin, EBER, phospho-GSK-3β, and Fascin-1. WHO II+III tumors were more frequently EBER & PTEN positive and VEGF-A negative. Advanced age was significantly associated with positive phospho-GSK-3β and ERCC1 expression; male gender with positive phospho-AKT and phospho-p44/42MAPK; and worse performance status (1 or 2) with negative Ki67, ERCC1, PTEN, and phospho-mTOR expression. Earlier disease stage was closely associated with p63, MAPT, PTEN, and Cyclin D1 positivity. Univariate Cox regression analysis highlighted Cyclin D1 as a negative prognostic factor for disease-free survival (p=0.034) and EBER as a positive one for overall survival (p=0.048). In multivariate analysis, advanced age and stage, poor performance status, and positive ERCC1 emerged as predictors of worse disease-free and overall survival, as opposed to positive phospho-mTOR. Clustering analysis defined two protein-expression groups being predictive of better overall survival (p=0.043).

Conclusions

Our study is the first to examine the activation and interaction of established biomolecules and signaling pathways in Caucasian NPC patients in an effort to reveal new therapeutic targets.

【 授权许可】

   
2013 Krikelis et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006, 15(10):1765-1777.
• [2]Curado MP, Edwards B, Shin H, Storm H, Ferlay J, Heanue M, Boyle P: Cancer Incidence in Five Continents. Lyon, France: IARC Scientific Publications; 2007.
• [3]Dancey JE, Bedard PL, Onetto N, Hudson TJ: The genetic basis for cancer treatment decisions. Cell 2012, 148(3):409-420.
• [4]Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al.: Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005, 61(4):1107-1116.
• [5]Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, Zaramboukas T, Nikolaou A, Markou K, Resiga L, et al.: Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol 2012, 23(2):427-435.
• [6]Chang KL, Chen YY, Shibata D, Weiss LM: Description of an in situ hybridization methodology for detection of epstein-barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992, 1(4):246-255.
• [7]Hwang CF, Cho CL, Huang CC, Wang JS, Shih YL, Su CY, Chang HW: Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol 2002, 13(8):1246-1251.
• [8]Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al.: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750.
• [9]Dabbs DJ, Sturtz K, Zaino RJ: The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol 1996, 27(2):172-177.
• [10]Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, Samantas E, Christodoulou C, Pentheroudakis G, Pectasides D, et al.: A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010, 65(6):1009-1021.
• [11]Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO: Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006, 208(4):495-506.
• [12]Fan SQ, Ma J, Zhou J, Xiong W, Xiao BY, Zhang WL, Tan C, Li XL, Shen SR, Zhou M, et al.: Differential expression of epstein-barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis. Hum Pathol 2006, 37(5):593-605.
• [13]McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23(36):9067-9072.
• [14]Yip WK, Leong VC, Abdullah MA, Yusoff S, Seow HF: Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep 2008, 19(2):319-328.
• [15]Lee SC, Lim SG, Soo R, Hsieh WS, Guo JY, Putti T, Tao Q, Soong R, Goh BC: Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics 2006, 16(1):73-74.
• [16]Sun LM, Li CI, Huang EY, Vaughan TL: Survival differences by race in nasopharyngeal carcinoma. Am J Epidemiol 2007, 165(3):271-278.
• [17]Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM: Nasopharyngeal carcinoma–review of the molecular mechanisms of tumorigenesis. Head Neck 2008, 30(7):946-963.
• [18]Jiong L, Berrino F, Coebergh JW: Variation in survival for adults with nasopharyngeal cancer in Europe, 1978–1989. EUROCARE Working Group. Eur J Cancer 1998, 34(14 Spec No):2162-2166.
• [19]Ertan Y, Hekimgil M, Karaarslan S, Soydan S: Expression of epstein-barr-virus-encoded small nuclear RNA in nasopharyngeal carcinomas of aegean Turkish patients. Virchows Arch 2008, 452(4):411-414.
• [20]d’Espiney Amaro C, Montalvao P, Henriques P, Magalhaes M, Olias J: Nasopharyngeal carcinoma: our experience. Eur Arch Otorhinolaryngol 2009, 266(6):833-838.
• [21]Terzic TT, Boricic MI, Pendjer IP, Ruzic Zecevic DT, Tomanovic NR, Brasanac DC, Boricic IV: Prognostic significance of clinical parameters and epstein-barr virus infection in non-endemic undifferentiated carcinoma of nasopharyngeal type: a serbian report. Med Oncol 2011, 28(4):1325-1330.
• [22]Sidler D, Thum P, Winterhalder R, Huber G, Haerle SK: Undifferentiated carcinoma of nasopharyngeal type (UCNT): a Swiss single-institutional experience during 1990–2005. Swiss Med Wkly 2010, 140(19–20):273-279.
• [23]Pasini E, Caggiari L, Dal Maso L, Martorelli D, Guidoboni M, Vaccher E, Barzan L, Franchin G, Gloghini A, De Re V, et al.: Undifferentiated nasopharyngeal carcinoma from a nonendemic area: protective role of HLA allele products presenting conserved EBV epitopes. Int J Cancer 2009, 125(6):1358-1364.
• [24]Nakao K, Mochiki M, Nibu K, Sugasawa M, Uozaki H: Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for epstein-barr virus encoded small RNA 1. Otolaryngol Head Neck Surg 2006, 134(4):639-645.
• [25]Hui AB, Or YY, Takano H, Tsang RK, To KF, Guan XY, Sham JS, Hung KW, Lam CN, van Hasselt CA, et al.: Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 2005, 65(18):8125-8133.
• [26]Ong CS, Zhou J, Ong CN, Shen HM: Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3beta-Cyclin D1 pathway. Cancer Lett 2010, 298(2):167-175.
• [27]Yoo SS, Carter D, Turner BC, Sasaki CT, Son YH, Wilson LD, Glazer PM, Haffty BG: Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer 2000, 90(1):22-28.
• [28]Turner BC, Gumbs AA, Carter D, Glazer PM, Haffty BG: Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. Int J Radiat Oncol Biol Phys 2000, 47(5):1169-1176.
• [29]Crook T, Nicholls JM, Brooks L, O’Nions J, Allday MJ: High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 2000, 19(30):3439-3444.
• [30]Fotheringham JA, Mazzucca S, Raab-Traub N: Epstein-Barr virus latent membrane protein-2A-induced DeltaNp63alpha expression is associated with impaired epithelial-cell differentiation. Oncogene 2010, 29(30):4287-4296.
• [31]Chiang CT, Chu WK, Chow SE, Chen JK: Overexpression of delta Np63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation. J Cell Physiol 2009, 219(1):117-122.
• [32]Huang GW, Mo WN, Kuang GQ, Nong HT, Wei MY, Sunagawa M, Kosugi T: Expression of p16, nm23-H1, E-cadherin, and CD44 gene products and their significance in nasopharyngeal carcinoma. Laryngoscope 2001, 111(8):1465-1471.
• [33]Chow LS, Wang X, Kwong DL, Sham JS, Tsao SW, Nicholls JM: Effect of p16INK4a on chemosensitivity in nasopharyngeal carcinoma cells. Int J Oncol 2000, 17(1):135-140.
• [34]Lin HS, Berry GJ, Sun Z, Fee WE Jr: Cyclin D1 and p16 expression in recurrent nasopharyngeal carcinoma. World J Surg Oncol 2006, 4:62. BioMed Central Full Text
• [35]Makitie AA, MacMillan C, Ho J, Shi W, Lee A, O’Sullivan B, Payne D, Pintilie M, Cummings B, Waldron J, et al.: Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003, 9(6):2177-2184.
• [36]Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N: Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 2004, 64(15):5251-5260.
• [37]Mei YP, Zhou JM, Wang Y, Huang H, Deng R, Feng GK, Zeng YX, Zhu XF: Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 2007, 6(11):1379-1385.
• [38]Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, Chan AT: The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs 2010, 28(4):413-420.
• [39]Liu Y, Chen LH, Yuan YW, Li QS, Sun AM, Guan J: Activation of AKT is associated with metastasis of nasopharyngeal carcinoma. Tumour Biol 2012, 33(1):241-245.
• [40]Yip WK, Seow HF: Activation of phosphatidylinositol 3-kinase/Akt signaling by EGF downregulates membranous E-cadherin and beta-catenin and enhances invasion in nasopharyngeal carcinoma cells. Cancer Lett 2012, 318(2):162-172.
• [41]Krishna SM, Kattoor J, Balaram P: Down regulation of adhesion protein E-cadherin in epstein-barr virus infected nasopharyngeal carcinomas. Cancer Biomark 2005, 1(6):271-277.
• [42]Galera-Ruiz H, Rios MJ, Gonzalez-Campora R, de Miguel M, Carmona MI, Moreno AM, Galera-Davidson H: The cadherin-catenin complex in nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 2011, 268(9):1335-1341.
• [43]Zheng Z, Pan J, Chu B, Wong YC, Cheung AL, Tsao SW: Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol 1999, 30(4):458-466.
• [44]Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992, 84(19):1512-1517.
• [45]Lee HW, Hwang YH, Han JH, Choi JH, Kang SY, Jeong SH, Ann MS, Oh YT, Kim JH, Kim CH, et al.: High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol 2010, 46(3):209-213.
• [46]Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, et al.: The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009, 119(12):3626-3636.
• [47]Xu X, Yang H, Huo X: [Expression and significance of PTEN in nasopharyngeal carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2004, 18(11):658-659.
• [48]Peng JP, Chang HC, Hwang CF, Hung WC: Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis. Oral Oncol 2005, 41(9):903-908.
• [49]Liu Y, Zhao S, Liu G, Li Z, Sun Z, Jiang W: [The value of cyclooxygenase-2 to predict the effect of radiotherapy in nasopharyngeal carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2007, 21(5):199-202.
• [50]Tan KB, Putti TC: Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. J Clin Pathol 2005, 58(5):535-538.
• [51]Kim YJ, Go H, Wu HG, Jeon YK, Park SW, Lee SH: Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck 2011, 33(10):1458-1466.
• [52]Loong SL, Hwang JS, Li HH, Wee JT, Yap SP, Chua ML, Fong KW, Tan TW: Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). Radiat Oncol 2009, 4:23. BioMed Central Full Text
• [53]Pan J, Kong L, Lin S, Chen G, Chen Q, Lu JJ: The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma. Laryngoscope 2008, 118(11):1970-1975.
• [54]Soo R, Putti T, Tao Q, Goh BC, Lee KH, Kwok-Seng L, Tan L, Hsieh WS: Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression. Arch Otolaryngol Head Neck Surg 2005, 131(2):147-152.
• [55]Fendri A, Khabir A, Hadhri-Guiga B, Sellami-Boudawara T, Ghorbel A, Daoud J, Frikha M, Jlidi R, Gargouri A, Mokdad-Gargouri R: Overexpression of COX-2 and LMP1 are correlated with lymph node in Tunisian NPC patients. Oral Oncol 2008, 44(7):710-715.
• [56]Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, Pagano JS: Induction of cyclooxygenase-2 by epstein-barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001, 98(12):6905-6910.
• [57]Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, et al.: Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 2008, 29(10):1930-1937.
• [58]Sheu LF, Chen A, Tseng HH, Leu FJ, Lin JK, Ho KC, Meng CL: Assessment of p53 expression in nasopharyngeal carcinoma. Hum Pathol 1995, 26(4):380-386.
• [59]Chow LW, Khoo US, Yuen AP, Wei WI: Expression of p53 in recurrent nodal metastasis from nasopharyngeal carcinoma (NPC). Eur J Surg Oncol 1997, 23(5):415-418.
• [60]Liu QY, Han AJ, You SY, Dong Y, Yang QX, Wu JH, Li MF: [Correlation of epstein-barr virus-encoded latent membrane protein 1 (LMP1) to fascin and phosphorylated Stat3 in nasopharyngeal carcinoma]. Ai Zheng 2008, 27(10):1070-1076.
• [61]Cao XJ, Hao JF, Yang XH, Xie P, Liu LP, Yao CP, Xu J: Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma. Med Oncol 2012, 29(1):263-271.
• [62]Taheri-Kadkhoda Z, Magnusson B, Svensson M, Mercke C, Bjork-Eriksson T: Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck 2009, 31(4):482-492.
• [63]Kung CP, Meckes DG Jr, Raab-Traub N: Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J Virol 2011, 85(9):4399-4408.
• [64]Ruan L, Li XH, Wan XX, Yi H, Li C, Li MY, Zhang PF, Zeng GQ, Qu JQ, He QY, et al.: Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics. Proteome Sci 2011, 9:35. BioMed Central Full Text
• [65]Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BK, Ahuja A, et al.: A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2012, 23(5):1287-1292.
• [66]Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al.: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359(11):1116-1127.
• [67]Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, et al.: Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002, 8(8):2595-2604.
• [68]Wakisaka N, Wen QH, Yoshizaki T, Nishimura T, Furukawa M, Kawahara E, Nakanishi I: Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope 1999, 109(5):810-814.
• [69]Shi XY, Hu GQ, Yuan XL, Li HY, Liu YQ, Ma D: [Relationship between VEGF-C expression and nasopharyngeal carcinoma proliferation and metastasis]. Zhonghua Zhong Liu Za Zhi 2006, 28(5):364-367.
• [70]Yi X, Tang A, Qin Y, Wen W, Zhao W: [Expression and relationship of EBV LMP1, COX-2 and VEGF-C in nasopharyngeal carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2010, 24(3):126-128.
• [71]Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, Hu K, Le QT, Colevas AD, Glisson BS, et al.: Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012, 13(2):172-180.
• [72]Sabatini DM: mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6(9):729-734.
• [73]Chen J, Hu CF, Hou JH, Shao Q, Yan LX, Zhu XF, Zeng YX, Shao JY: Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J Transl Med 2010, 8:30. BioMed Central Full Text
• [74]Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al.: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486(7403):346-352.
• [75]Huang C, Tang H, Zhang W, She X, Liao Q, Li X, Wu M, Li G: Integrated analysis of multiple gene expression profiling datasets revealed novel gene signatures and molecular markers in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2012, 21(1):166-175.
• [76]Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL, et al.: Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. J Clin Oncol 2011, 29(34):4516-4525.
• [77]Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, et al.: A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008, 7(10):1998-2018.